Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Sjögren’s Syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands and results in keratoconjunctivitis sicca (KCS [dry eye disease]) and/or stomatitis sicca (dry mouth disease). Though sometimes referred to as “sicca syndrome,” referring to dryness of the exocrine glands, symptoms that most SS patients do display, a patient is only classified as having sicca when there is no evidence of the presence of an autoimmune disease. Although SS is only one of the many diseases that cause dry eyes and mouth, it is one of the most severe. The most characteristic clinical features are ocular and oral dryness due to reduced secretory functions; however, systemic features including cutaneous, respiratory, renal, hepatic, neurological, and vascular involvement often occur. In addition, there is a higher incidence of lymphoma associated with SS patients.
Sjogrens syndrome marketed and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with Phase transition success rate (PTSR), and likelihood of approval (LoA) for Sjogren’s syndrome. The report also analyzes the clinical and commercial landscapes of Sjogren’s syndrome, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Key Regions in the Sjogrens Syndrome Clinical Trials Market
Key regions in the Sjogrens syndrome clinical trails market are Asia-Pacific, North America, Europe, Middle East & Africa, South and Central America. Amongst all single-country trials were most numerous in the Asia-Pacific.
Sjogrens Syndrome Clinical Trials Market, by Regions
For more regional insights, download a free report sample
Key MoA in the Sjogrens Syndrome Pipeline Market
Key MoA in the Sjogrens syndrome pipeline market are receptor antagonist, biological factor inhibitor, enzyme inhibitor, cytotoxic to cell, protein and peptide inhibitor, receptor agonist, and others. Most of the pipeline drugs undergoing development for SS with a known mechanism of action are receptor antagonists.
Sjogrens Syndrome Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Sjogrens Syndrome Pipeline Market
Key RoA in the Sjogrens syndrome pipeline market are oral, injection, and topical. Of the pipeline drugs undergoing development for SS with a known route of administration, injectable therapies are the most common route of delivery.
Sjogrens Syndrome Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Sjogrens Syndrome Pipeline Market
Key molecule type in the Sjogrens syndrome pipeline market are biologic and small molecule. Biologics has the highest share among the two molecule types.
Sjogrens Syndrome Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Sponsors in the Sjogrens Syndrome Clinical Trial Market
- Novartis AG
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Viela Bio Inc
- Cairo University
- TearSolutions Inc
- University Medical Center Groningen
- Others
Sjogrens Syndrome Clinical Trials Market, by Sponsors
To know more about sponsors, download a free report sample
Market report overview
Key regions | Asia-Pacific, North America, Europe, Middle East & Africa, South and Central America |
Key MoA | Receptor Antagonist, Biological Factor Inhibitor, Enzyme Inhibitor, Cytotoxic to Cell, Protein and Peptide Inhibitor, Receptor Agonist, and Others |
Key RoA | Oral, Injection, and Topical |
Key molecule type | Biologic and Small Molecule |
Key sponsors | Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, Viela Bio Inc, Cairo University, TearSolutions Inc, University Medical Center Groningen, and Others |
Scope
- GlobalData’s Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Sjogren’s Syndrome market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sjogren’s Syndrome market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key regions in the Sjogrens syndrome clinical trials market?
The key regions in the Sjogrens syndrome clinical trials market are Asia-Pacific, North America, Europe, Middle East & Africa, South and Central America.
-
What are the key MoA in the Sjogrens syndrome pipeline market?
The key MoA in the Sjogrens syndrome pipeline market are receptor antagonist, biological factor inhibitor, enzyme inhibitor, cytotoxic to cell, protein and peptide inhibitor, receptor agonist, and others.
-
What are the key RoA in the Sjogrens syndrome pipeline market?
The key RoA in the Sjogrens syndrome pipeline market are oral, injection, and topical.
-
What are the key molecule types in the Sjogrens syndrome pipeline market?
The key molecule types in the Sjogrens syndrome pipeline market are biologic and small molecule.
-
Which are the key sponsors in the Sjogrens syndrome clinical trials market?
The key sponsors in the Sjogrens syndrome clinical trials market are Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, Viela Bio Inc, Cairo University, TearSolutions Inc, University Medical Center Groningen, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.